VSTMVerastem, Inc.
$3.45-24% 1Y
$3.45
$3.4552 weeks$10.64
VSTM in its own filings
VSTM's filing record carries one kind of hard flag, each is shown beside the share of the whole market carrying the same one, because more than half of all companies carry at least one.
262
Events found in the filings · across 1,047 filings · the record starts in 2011
- Hard flags
- 1
Hard flags
- Most recent filing
- Aug 7, 2026
Most recent filing · Form 8-K
- Record starts
- Dec 1, 2011
Record starts · the earliest filing Ryufin holds for this name
Details›
- Next results filingsame week as a year ago
- expected around Nov 3, 2026
- Delisting notice / listing-rule failurehistorical
- 2022-11-09
- SEC comment-letter activity26 occurrences
- 2025-08-13
SEC EDGAR submissions index and 8-K item codes; 4.02 and 1.03 items are confirmed against the filing text.
What the company said
The company's own words from its current reports to the SEC, newest first
- Aug 7, 2026On August 6, 2026 (the “Amendment Closing Date”), Verastem, Inc., (the “Company”) entered into Amendment No. 3 (the “Amendment”) to that certain Note Purchase Agreement, dated as of January 13, 2025 (the “Original Closing Date”), as previously amended by Amendment No. 1 dated as of October 31, 2025 and Amendment No. 2 …Material agreement entered · Form 8-K
- Aug 6, 2026Verastem Oncology Reports Second Quarter 2026.Earnings release · press release
- Jun 23, 2026On June 23, 2026, the Company also (i) announced preliminary data from the ongoing TARGET-D 101 Phase 1/2 clinical trial evaluating VS-7375 in patients with advanced KRAS G12D-mutated solid tumors and provided an update on the status of expected key milestones in the development of VS-7375 and (ii) announced its …Regulation FD disclosure · Form 8-K
- Jun 17, 2026Positive Updated Results from RAMP 205 Evaluating Avutometinib Plus Defactinib in Combination with Standard-of-Care Chemotherapy in First-Line Metastatic Pancreatic Cancer On June 17, 2026, the Company announced positive updated safety and efficacy results from the RAMP 205 Phase 1b/2a trial Recommended Phase 2 Dose …Regulation FD disclosure · Form 8-K
- May 7, 2026RAS/MAPK Pathway-Driven Cancers.Regulation FD disclosure · press release
- Mar 4, 2026RAS/MAPK Pathway-Driven Cancers.Regulation FD disclosure · press release
- Feb 4, 2026Verastem Oncology Provides Preliminary Fourth.Earnings release · press release
- Jan 8, 2026Delivering Novel Therapies for RAS/MAPK Pathway - Driven Cancers CORPORATE PRESENTATION JANUARY 2026.Regulation FD disclosure · press release
- Dec 31, 2025Recent Developments Update on RAMP 203 Phase 1/2 Clinical Trial for Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer Following evaluation of interim data from the RAMP 203 clinical trial in advanced KRAS G12C-mutated NSCLC the Company will discontinue the trial to focus resources on clinical development of …Regulation FD disclosure · Form 8-K
- Dec 19, 2025Departure of Chief Operating Officer As previously disclosed on December 15, 2025, as of December 19, 2025, Matthew Ros separated from Verastem, Inc. (the "Company") as its Chief Operating Officer.Director or officer change · Form 8-K
- Nov 17, 2025On November 13, 2025, Verastem, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Jefferies LLC and Guggenheim Securities, LLC, as representatives of the several underwriters named in Schedule A thereto (the “Underwriters”), relating to the underwritten public offering …Other event · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
opening the record…